The development of further dual GLP-1/GIP receptor agonists seems to be a promising next step in managing various cardiovascular disease
However, no single GLP-1 is definitively 'easiest' for everyone, and careful dose titration alongside dietary adjustments can significantly improve tolerability across all agents
[3] [5] More serious but rare adverse effects can include pancreatitis (seek urgent medical attention for severe, persistent abdominal pain, especially if accompanied by vomiting) and gallbladder disease
We describe prescribing volumes and patient characteristics over time, by medication, and by FDA-labeled use (e.g., ADM, AOM, or unknown)
These are prescribed selectively and monitored closely
Leptin - insulin lipostat Although there is rather low local expression of leptin in the stomach, probably responsible for local antagonism of gastric release of ghrelin and named "leptin/ghrelin tango" operating along the brain-gut axis (9, 52), leptin belongs together with insulin to a "lipostat" substances that play a role in adiposity signaling ( Fig
